Vivo Capital LLC Raises Stake in Delcath Systems, Inc. (NASDAQ:DCTH)

Vivo Capital LLC grew its holdings in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 71.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,708,579 shares of the company's stock after buying an additional 711,574 shares during the period. Delcath Systems makes up 2.3% of Vivo Capital LLC's investment portfolio, making the stock its 8th largest holding. Vivo Capital LLC owned about 5.34% of Delcath Systems worth $20,571,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of DCTH. Quantbot Technologies LP acquired a new position in shares of Delcath Systems during the fourth quarter worth approximately $66,000. Geode Capital Management LLC raised its holdings in Delcath Systems by 3.0% during the third quarter. Geode Capital Management LLC now owns 251,895 shares of the company's stock worth $2,275,000 after buying an additional 7,298 shares during the last quarter. Riverwater Partners LLC lifted its stake in shares of Delcath Systems by 46.2% in the fourth quarter. Riverwater Partners LLC now owns 27,229 shares of the company's stock valued at $328,000 after buying an additional 8,601 shares in the last quarter. State Street Corp grew its holdings in shares of Delcath Systems by 12.4% during the third quarter. State Street Corp now owns 85,457 shares of the company's stock valued at $772,000 after buying an additional 9,400 shares during the last quarter. Finally, Barclays PLC bought a new stake in shares of Delcath Systems during the third quarter worth about $104,000. Institutional investors and hedge funds own 61.12% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. HC Wainwright lifted their price target on Delcath Systems from $22.00 to $24.00 and gave the company a "buy" rating in a research note on Friday, March 7th. Craig Hallum lifted their target price on Delcath Systems from $18.00 to $21.00 and gave the company a "buy" rating in a research report on Friday, January 17th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $22.75.

Delcath Systems Stock Performance

Shares of Delcath Systems stock traded up $0.05 during mid-day trading on Friday, hitting $12.11. 187,555 shares of the stock were exchanged, compared to its average volume of 355,978. Delcath Systems, Inc. has a 12 month low of $5.12 and a 12 month high of $16.97. The company has a 50-day simple moving average of $12.69 and a 200 day simple moving average of $12.37. The company has a market capitalization of $404.87 million, a P/E ratio of -8.97 and a beta of 0.85.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. The business had revenue of $15.10 million during the quarter, compared to analysts' expectations of $14.96 million. During the same period in the prior year, the firm posted ($0.48) EPS. Analysts predict that Delcath Systems, Inc. will post -0.79 EPS for the current year.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.